Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Choseido Likely to Face Administrative Penalty over Manufacturing Flaws
Choseido Pharmaceutical looks set to face an administrative penalty as early as September over generic manufacturing issues deemed to constitute a violation of the Pharmaceutical and Medical Devices (PMD) Law, people familiar with the matter told Jiho. The government of…
To read the full story
Related Article
- Lack of Management Response, Tight Manufacturing Plans to Blame in Choseido Issue: Report
October 12, 2021
- Choseido Woes Cast Clouds on Generic Inroads in Tokushima, Worst Player in Penetration
October 12, 2021
- Choseido Hit by Biz Suspension of Up to 31 Days over Manufacturing Flaws
October 11, 2021
- One-Month Business Suspension Order Likely for Choseido over Generic Recalls
September 24, 2021
- Shipments of 64 Choseido-Made Products Now Adjusted or Halted
August 20, 2021
- Shipment Adjustments/Pauses for Choseido-Made Products Grow to 42
July 20, 2021
- Snap Inspections at Generic Plants Conducted in 46 Prefectures, Results Due Out in August
July 16, 2021
- Flawed Stability Tests Found for 31 Choseido-Manufactured Products, Recalls Hit 15
May 25, 2021
BUSINESS
- Toho Subsidiary Suffers Data Breach, HCP Info Exposed
October 20, 2026
- Veritas, Toray Pin Down Hit Compounds for PCSK9 mRNA Drugs
October 20, 2026
- Insmed’s Brinsupri Hits Japan Market for NCFB
October 20, 2026
- Ex-Alfresa Chairman Arata Watanabe Dies at 85
October 20, 2026
- TS Alfresa-Backed Drone Council Inks Pact with Hiroshima
October 19, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…